news
MHRA approve first monoclonal antibody treatment for COVID-19
The MHRA have approved Ronapreve as the first monoclonal antibody combination product for the treatment of COVID-19 infection in the UK.
List view / Grid view
Oxford University
article
Boom times for pharma M&A
Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803-300x278.jpg)
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803.jpg)
news
AstraZeneca’s COVID-19 vaccine prevents severe disease and hospitalisation in Phase III trials
A preliminary analysis suggests the COVID-19 Vaccine AstraZeneca was 74 percent effective after the first dose and 82 percent effective with a 12-week inter-dose interval.
news
AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
article
Radical innovation occurs when pharma looks outside its own world
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
news
Hydroxychloroquine has no benefit to patients hospitalised with COVID-19, finds trial
The RECOVERY trial has stopped enrolment for the hydroxychloroquine arm after data revealed the drug had no meaningful benefit for hospitalised COVID-19 patients.
news
Less than half of US clinical trials comply with reporting regulations
Researchers have found that only 41 percent of trials reported their findings with a year after completion and suggest that over $4 billion in fines could have been collected in just 12 months.
news
Sir Peter Ratcliffe awarded joint Nobel Prize for Physiology or Medicine
The researcher Sir Peter Ratcliffe and two others have been jointly awarded the Nobel Prize for Physiology or Medicine 2019.
content_hub
Infectious Diseases Data Observatory
29 March 2018 | By
Poor quality medicines threaten us all, but have the greatest impact on vulnerable populations in countries with inadequate medicine laws and regulation. Keeping patients safe and ensuring that the benefits of modern medicine are delivered to those in need are the key goals of a wide range of organisations which…
news
A pioneering conference will address the threat of poor quality medicines on a global scale
A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health...
